Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

LY3410738 , CAS No.2230263-60-0, Inhibitor of isocitrate dehydrogenase (NADP(+)) 1;Inhibitor of isocitrate dehydrogenase (NADP(+)) 2

Item Number
L611657
Grouped product items
SKUSizeAvailabilityPrice Qty
L611657-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$920.90
L611657-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$3,700.90
Add to Wish List Compare
Bulk Order  SDS  DATASHEET
View related series
isocitrate dehydrogenase (NADP(+)) 1 Inhibitor isocitrate dehydrogenase (NADP(+)) 2 Inhibitor

Basic Description

Synonymsexample 2 [US11001596B2];LY-3410738
Specifications & PurityMoligand™
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of isocitrate dehydrogenase (NADP(+)) 1;Inhibitor of isocitrate dehydrogenase (NADP(+)) 2

Associated Targets(Human)

IDH1 Tclin Isocitrate dehydrogenase [NADP] cytoplasmic (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
IDH2 Tclin Isocitrate dehydrogenase [NADP], mitochondrial (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one
INCHI InChI=1S/C28H36N6O3/c1-4-25(35)33-14-12-32(13-15-33)24(16-20-6-7-20)22-10-8-21(9-11-22)19(3)30-27-29-17-23-18-37-28(36)34(5-2)26(23)31-27/h4,8-11,17,19-20,24H,1,5-7,12-16,18H2,2-3H3,(H,29,30,31)/t19-,24-/m0/s1
InChi Key AFGYODUJVVOZAX-CYFREDJKSA-N
Canonical SMILES CCN1c2nc(ncc2COC1=O)N[C@@H](C)c1ccc(cc1)[C@H](CC1CC1)N1CCN(CC1)C(=O)C=C
PubChem CID 135125140

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

 SDS

 Specification Sheet

References

1. Cleary JM, Rouaisnel B, Daina A, Raghavan S, Roller LA, Huffman BM, Singh H, Wen PY, Bardeesy N, Zoete V et al..  (2022)  Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma..  NPJ Precis Oncol,  6  (1): (61).  [PMID:36056177] [10.1021/op500134e]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.